English
Seeking the source of tuberculosis drug resistance
A targeted deep sequencing assay identifies multidrugresistant tuberculosis strains responsible for silent outbreaks
Yes we can, end TB!
For over a decade, GenoScreen has been committed to the fight against tuberculosis (TB), one of the deadliest infectious diseases in the world. The company's journey began with the groundbreaking development of MIRU-VNTR typing kits in 2013 which marked a turning point in TB research and control by enabling rapid and accurate identification of TB strains. This breakthrough technology provided an unparalleled level of resolution in characterizing TB strains, essential for the management and control of TB outbreaks, allowing researchers and public health authorities to track the spread of the disease more efficiently and prevent further outbreaks.
GenoScreen becomes a Certified Service Provider by Oxford Nanopore Technologies
GenoScreen is now a certified service provider of Oxford Nanopore Technologies.
GenoScreen and Illumina Partner to Expand Access to Genomic Testing for Multidrug-Resistant Tuberculosis
GenoScreen, world specialist in TB genomic solutions, and Illumina partner to expand access to a package combining Deeplex® Myc-TB assay and Illumina sequencing products.
Meet us at the 18th International Symposium on Microbial Ecology (ISME), Lausanne – Switzerland
The new edition of the International Symposium on Microbial Ecology a staple meeting in the field, will cover many topics, in environment, human and animal health, and bioprocesses.
Dr Philip Supply receives the Gardner Middlebrook Lifetime Achievement Award 2022
Dr Philip Supply, Director of Research at the CNRS and Scientific Adviser at GenoScreen, has received the prestigious Gardner Middlebrook Lifetime Achievement Award at the 42nd Annual Congress of the European Society of Mycobacteriology (ESM) on 26 June 2022 in Bologna – Italy.
Meet us at the 42nd Annual Congress of the European Society of Mycobacteriology (ESM) from June 26th to 29th in Bologna, Italy.
The program of this 42nd edition has for main topics Covid and Tuberculosis and will address new diagnostic strategies.
Subcategories
GenoScreen
Partners
At GenoScreen, our genomics expertise is built on collaboration with a dense network of scientific, industrial and institutional partners. These partnerships strengthen our ability to innovate, co-develop new technologies and advance research in molecular microbiology.
A network of strategic partners
We actively collaborate with:
Research institutes, universities and hospitals
Competitive clusters specialized in biotechnology and healthcare
Public funding bodies
A co-development strategy
Our research projects are carried out with recognized partners in France and abroad. Together, we can :
- Co-develop innovative genomics and bioinformatics solutions
- Reply to national and international applications for projects (Horizon Europe, ANR, etc.)
- Test and validate our technologies in a variety of environments
- Launch the implementation of concrete solutions for health, agriculture and the environment
Why collaborate with GenoScreen?
- Access to an innovative sequencing technology platform
- Access to recognized expertise in bioinformatics analysis and biomarkers
- Benefit from our ability to manage collaborative R&D projects
- Strive for health, agriculture and environment
Join our network of partners
Do you represent a company, laboratory or public body? Contact us to discuss a collaboration or partnership.
Frequently asked questions
What kind of partners work with GenoScreen?
GenoScreen works with academic laboratories, biotech companies and clusters.
What are the benefits of these partnerships?
They help us co-develop technologies, co-finance projects and accelerate innovation.
How can I propose a partnership?
You can contact us via our contact form to discuss your project and identify a potential collaboration.
Collaborative research - At the heart of international innovation in genomics
GenoScreen is a partner in collaborative research projects that bring together startups, multinationals and public-sector organizations. Our R&D teams provide their knowledge and expertise in the molecular microbiology of isolated agents and complex communities. This allowed our teams to develop our own projects for elaborating innovative products and services.
Our projects are designed to:
- Improve the diagnosis and management of acute/chronic diseases on humans and animals,
- Characterize and monitor microbial biodiversity, with applications in agronomy, agrifood and environment.
The common feature of these projects is the development of molecular tools for the characterization, monitoring and diagnosis of microbial communities. The key objective is to market simple analytical solutions and (ultimately) preventive, corrective or even therapeutic products based on microorganisms.